Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

A method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, the method comprising:

• orally administering an initial dose of between 75 mg and 300 mg xanomeline and/or a salt thereof and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, wherein the initial dose of trospium chloride is in an amount effective to reduce a side effect associated with the initial dose of xanomeline and/or the salt thereof;
• and
• orally administering to the patient an increased dose of trospium chloride and an increased dose of xanomeline and/or the salt thereof,
• wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and
• wherein the increased dose of xanomeline and/or the salt thereof is greater than the initial dose of the xanomeline and/or the salt thereof.